Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?

Takeshi Hatanaka, Atsushi Naganuma, Yutaka Yata, Satoru Kakizaki